Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Conditions: Advanced Cancer; Gastric Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer Metastatic; Colo-rectal Cancer; Solid Tumor; Solid Carcinoma; Solid Carcinoma of Stomach; Cancer of Stomach; Lymphoma; Sarcoma; Cutaneous T Cell Lymphoma; Head and Neck Squamous Cell Carcinoma; Basal Cell Carcinoma; Cutaneous T-cell Lymphoma; Cutaneous Squamous Cell Carcinoma
Interventions: Drug: GZ17-6.02; Drug: Capecitabine
Sponsors: Genzada Pharmaceuticals USA, Inc.; Translational Drug Development
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.